E2F1
Summary: The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids, and a tumor suppressor protein association domain which is embedded within the transactivation domain. This protein and another 2 members, E2F2 and E2F3, have an additional cyclin binding domain. This protein binds preferentially to retinoblastoma protein pRB in a cell-cycle dependent manner. It can mediate both cell proliferation and p53-dependent/independent apoptosis. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| E2F transcription factor 1 | MIM:189971 | Ensembl:ENSG00000101412 | HGNC:HGNC:3113 | PA152 | 20q11.22 |
GO terms in E2F1
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IMP | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | NAS | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | IDA | GO:0000987 | proximal promoter sequence-specific DNA binding |
| MF | IC | GO:0001227 | transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding |
| MF | IDA | GO:0003677 | DNA binding |
| MF | IMP | GO:0003677 | DNA binding |
| MF | IDA | GO:0003700 | DNA-binding transcription factor activity |
| MF | TAS | GO:0003700 | DNA-binding transcription factor activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IPI | GO:0008134 | transcription factor binding |
| MF | IEA | GO:0019901 | protein kinase binding |
| MF | IDA | GO:0043565 | sequence-specific DNA binding |
| MF | ISS | GO:0043565 | sequence-specific DNA binding |
| MF | IEA | GO:0046983 | protein dimerization activity |
| CC | IDA | GO:0000790 | nuclear chromatin |
| CC | IDA | GO:0005634 | nucleus |
| CC | IDA | GO:0005654 | nucleoplasm |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IEA | GO:0005739 | mitochondrion |
| CC | IDA | GO:0005813 | centrosome |
| CC | IDA | GO:0032991 | protein-containing complex |
| CC | IDA | GO:0035189 | Rb-E2F complex |
| BP | IMP | GO:0000077 | DNA damage checkpoint |
| BP | TAS | GO:0000083 | regulation of transcription involved in G1/S transition of mitotic cell cycle |
| BP | IMP | GO:0000122 | negative regulation of transcription by RNA polymerase II |
| BP | ISS | GO:0006351 | transcription, DNA-templated |
| BP | IDA | GO:0006355 | regulation of transcription, DNA-templated |
| BP | TAS | GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest |
| BP | IEA | GO:0007283 | spermatogenesis |
| BP | IMP | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage |
| BP | IDA | GO:0010628 | positive regulation of gene expression |
| BP | IEA | GO:0030900 | forebrain development |
| BP | IDA | GO:0043065 | positive regulation of apoptotic process |
| BP | IEA | GO:0043276 | anoikis |
| BP | IDA | GO:0043392 | negative regulation of DNA binding |
| BP | ISS | GO:0045599 | negative regulation of fat cell differentiation |
| BP | IDA | GO:0045892 | negative regulation of transcription, DNA-templated |
| BP | IMP | GO:0045892 | negative regulation of transcription, DNA-templated |
| BP | IDA | GO:0045893 | positive regulation of transcription, DNA-templated |
| BP | IMP | GO:0045893 | positive regulation of transcription, DNA-templated |
| BP | IMP | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IMP | GO:0048146 | positive regulation of fibroblast proliferation |
| BP | IDA | GO:0048255 | mRNA stabilization |
| BP | TAS | GO:0070317 | negative regulation of G0 to G1 transition |
| BP | ISS | GO:0070345 | negative regulation of fat cell proliferation |
| BP | IEA | GO:0071398 | cellular response to fatty acid |
| BP | IEA | GO:0071456 | cellular response to hypoxia |
| BP | IEA | GO:0071466 | cellular response to xenobiotic stimulus |
| BP | IMP | GO:0071930 | negative regulation of transcription involved in G1/S transition of mitotic cell cycle |
| BP | IEA | GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator |
| BP | TAS | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| BP | IEA | GO:1990086 | lens fiber cell apoptotic process |
| BP | IEA | GO:1990090 | cellular response to nerve growth factor stimulus |
| BP | IMP | GO:2000045 | regulation of G1/S transition of mitotic cell cycle |
Gene expression in normal tissue: E2F1
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in E2F1
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| biocarta | arfpathway | tumor suppressor arf inhibits ribosomal biogenesis |
| biocarta | cellcyclepathway | cyclins and cell cycle regulation |
| biocarta | etspathway | mets affect on macrophage differentiation |
| biocarta | fbw7pathway | cyclin e destruction pathway |
| biocarta | g1pathway | cell cycle: g1/s check point |
| biocarta | il2rbpathway | il-2 receptor beta chain in t cell activation |
| biocarta | p27pathway | regulation of p27 phosphorylation during cell cycle progression |
| biocarta | p53pathway | p53 signaling pathway |
| biocarta | raccycdpathway | influence of ras and rho proteins on g1 to s transition |
| biocarta | rbpathway | rb tumor suppressor/checkpoint signaling in response to dna damage |
| biocarta | skp2e2fpathway | e2f1 destruction pathway |
| reactome | R-HSA-109581 | Apoptosis |
| reactome | R-HSA-109606 | Intrinsic Pathway for Apoptosis |
| reactome | R-HSA-111448 | Activation of NOXA and translocation to mitochondria |
| reactome | R-HSA-113501 | Inhibition of replication initiation of damaged DNA by RB1/E2F1 |
| reactome | R-HSA-113510 | E2F mediated regulation of DNA replication |
| reactome | R-HSA-114452 | Activation of BH3-only proteins |
| reactome | R-HSA-1362277 | Transcription of E2F targets under negative control by DREAM complex |
| reactome | R-HSA-1362277 | Transcription of E2F targets under negative control by DREAM complex |
| reactome | R-HSA-1362300 | Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 |
| reactome | R-HSA-139915 | Activation of PUMA and translocation to mitochondria |
| reactome | R-HSA-1538133 | G0 and Early G1 |
| reactome | R-HSA-1538133 | G0 and Early G1 |
| reactome | R-HSA-157118 | Signaling by NOTCH |
| reactome | R-HSA-157118 | Signaling by NOTCH |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1640170 | Cell Cycle |
| reactome | R-HSA-1640170 | Cell Cycle |
| reactome | R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
| reactome | R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
| reactome | R-HSA-1912422 | Pre-NOTCH Expression and Processing |
| reactome | R-HSA-1912422 | Pre-NOTCH Expression and Processing |
| reactome | R-HSA-212436 | Generic Transcription Pathway |
| reactome | R-HSA-2262752 | Cellular responses to stress |
| reactome | R-HSA-2559580 | Oxidative Stress Induced Senescence |
| reactome | R-HSA-2559583 | Cellular Senescence |
| reactome | R-HSA-2559585 | Oncogene Induced Senescence |
| reactome | R-HSA-3700989 | Transcriptional Regulation by TP53 |
| reactome | R-HSA-453274 | Mitotic G2-G2/M phases |
| reactome | R-HSA-453279 | Mitotic G1-G1/S phases |
| reactome | R-HSA-453279 | Mitotic G1-G1/S phases |
| reactome | R-HSA-5357801 | Programmed Cell Death |
| reactome | R-HSA-539107 | Activation of E2F1 target genes at G1/S |
| reactome | R-HSA-539107 | Activation of E2F1 target genes at G1/S |
| reactome | R-HSA-6791312 | TP53 Regulates Transcription of Cell Cycle Genes |
| reactome | R-HSA-6804116 | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest |
| reactome | R-HSA-68689 | CDC6 association with the ORC:origin complex |
| reactome | R-HSA-68867 | Assembly of the pre-replicative complex |
| reactome | R-HSA-68874 | M/G1 Transition |
| reactome | R-HSA-68911 | G2 Phase |
| reactome | R-HSA-69002 | DNA Replication Pre-Initiation |
| reactome | R-HSA-69202 | Cyclin E associated events during G1/S transition |
| reactome | R-HSA-69205 | G1/S-Specific Transcription |
| reactome | R-HSA-69205 | G1/S-Specific Transcription |
| reactome | R-HSA-69206 | G1/S Transition |
| reactome | R-HSA-69206 | G1/S Transition |
| reactome | R-HSA-69231 | Cyclin D associated events in G1 |
| reactome | R-HSA-69236 | G1 Phase |
| reactome | R-HSA-69242 | S Phase |
| reactome | R-HSA-69278 | Cell Cycle, Mitotic |
| reactome | R-HSA-69278 | Cell Cycle, Mitotic |
| reactome | R-HSA-69306 | DNA Replication |
| reactome | R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry |
| reactome | R-HSA-73857 | RNA Polymerase II Transcription |
| reactome | R-HSA-74160 | Gene expression (Transcription) |
| reactome | R-HSA-8953750 | Transcriptional Regulation by E2F6 |
| reactome | R-HSA-8953897 | Cellular responses to external stimuli |
| wikipathways | WP1530 | miRNA Regulation of DNA Damage Response |
| wikipathways | WP1545 | miRNAs involved in DNA damage response |
| wikipathways | WP179 | Cell Cycle |
| wikipathways | WP1858 | Mitotic G1-G1-S phases |
| wikipathways | WP1984 | Integrated Breast Cancer Pathway |
| wikipathways | WP2002 | miR-targeted genes in epithelium - TarBase |
| wikipathways | WP2004 | miR-targeted genes in lymphocytes - TarBase |
| wikipathways | WP2005 | miR-targeted genes in muscle cell - TarBase |
| wikipathways | WP2032 | Human Thyroid Stimulating Hormone (TSH) signaling pathway |
| wikipathways | WP2261 | Signaling Pathways in Glioblastoma |
| wikipathways | WP236 | Adipogenesis |
| wikipathways | WP2431 | Spinal Cord Injury |
| wikipathways | WP2446 | Retinoblastoma (RB) in Cancer |
| wikipathways | WP2586 | Aryl Hydrocarbon Receptor |
| wikipathways | WP2815 | Mammary gland development pathway - Involution (Stage 4 of 4) |
| wikipathways | WP2828 | Bladder Cancer |
| wikipathways | WP3584 | MECP2 and Associated Rett Syndrome |
| wikipathways | WP3804 | TP53 Regulates Transcription of Cell Cycle Genes |
| wikipathways | WP3969 | H19 action Rb-E2F1 signaling and CDK-?-catenin activity |
| wikipathways | WP3998 | Prader-Willi and Angelman Syndrome |
| wikipathways | WP437 | EGF-EGFR Signaling Pathway |
| wikipathways | WP45 | G1 to S cell cycle control |
| wikipathways | WP615 | Senescence and Autophagy in Cancer |
| wikipathways | WP707 | DNA Damage Response |
| pid | e2f_pathway | E2F transcription factor network |
| pid | hes_heypathway | Notch-mediated HES/HEY network |
| pid | il2_pi3kpathway | IL2 signaling events mediated by PI3K |
| pid | nfat_tfpathway | Calcineurin-regulated NFAT-dependent transcription in lymphocytes |
| pid | p53downstreampathway | Direct p53 effectors |
| pid | p75ntrpathway | p75(NTR)-mediated signaling |
| pid | rb_1pathway | Regulation of retinoblastoma protein |
| pid | telomerasepathway | Regulation of Telomerase |
| kegg | hsa04110 | Cell cycle - Homo sapiens (human) |
| kegg | hsa04137 | Mitophagy - animal - Homo sapiens (human) |
| kegg | hsa04218 | Cellular senescence - Homo sapiens (human) |
| kegg | hsa04934 | Cushing,s syndrome - Homo sapiens (human) |
| kegg | hsa05161 | Hepatitis B - Homo sapiens (human) |
| kegg | hsa05165 | Human papillomavirus infection - Homo sapiens (human) |
| kegg | hsa05166 | HTLV-I infection - Homo sapiens (human) |
| kegg | hsa05167 | Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05206 | MicroRNAs in cancer - Homo sapiens (human) |
| kegg | hsa05212 | Pancreatic cancer - Homo sapiens (human) |
| kegg | hsa05214 | Glioma - Homo sapiens (human) |
| kegg | hsa05215 | Prostate cancer - Homo sapiens (human) |
| kegg | hsa05218 | Melanoma - Homo sapiens (human) |
| kegg | hsa05219 | Bladder cancer - Homo sapiens (human) |
| kegg | hsa05220 | Chronic myeloid leukemia - Homo sapiens (human) |
| kegg | hsa05222 | Small cell lung cancer - Homo sapiens (human) |
| kegg | hsa05223 | Non-small cell lung cancer - Homo sapiens (human) |
| kegg | hsa05224 | Breast cancer - Homo sapiens (human) |
| kegg | hsa05225 | Hepatocellular carcinoma - Homo sapiens (human) |
| kegg | hsa05226 | Gastric cancer - Homo sapiens (human) |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD283 | Bosutinib | 1 |
| iGMDRD781 | Sirolimus | 1 |
| iGMDRD397 | Pazopanib | 2 |
| iGMDRD546 | BMS-754807 | 4 |
| iGMDRD76 | Simvastatin | 1 |
| iGMDRD222 | HC-067047 | 1 |
| iGMDRD151 | CHM-1 | 1 |
| iGMDRD488 | KU-60019 | 1 |
| iGMDRD639 | YK 4-279 | 3 |
| iGMDRD316 | N9-Isopropyl-olomoucine | 1 |
| iGMDRD61 | Kinetin riboside | 3 |
| iGMDRD107 | Valdecoxib | 1 |
| iGMDRD285 | PYR-41 | 1 |
| iGMDRD106 | Clofarabine | 1 |
| iGMDRD117 | Docetaxel | 1 |
| iGMDRD513 | BML-259 | 2 |
| iGMDRD874 | BRD8958 | 1 |
| iGMDRD64 | Parbendazole | 3 |
| iGMDRD888 | Compound 44 | 3 |
| iGMDRD146 | Elesclomol | 1 |
| iGMDRD188 | Piperlongumine | 1 |
| iGMDRD399 | Selumetinib | 1 |
| iGMDRD405 | PIK-75 | 3 |
| iGMDRD1036 | X17AAG | 1 |
| iGMDRD324 | CI-1040 | 1 |
| iGMDRD123 | Isoevodiamine | 4 |
| iGMDRD314 | Tanespimycin | 1 |
| iGMDRD352 | PD-0325901 | 1 |
| iGMDRD540 | Alisertib | 1 |
| iGMDRD105 | Triptolide | 2 |
| iGMDRD103 | SN-38 | 6 |
| iGMDRD202 | Curcumin | 6 |
| iGMDRD527 | GSK 1059615 | 1 |
| iGMDRD329 | Merck60 | 1 |
| iGMDRD366 | PI-103 | 1 |
| iGMDRD561 | ABT-263 | 1 |
| iGMDRD871 | BRD6368 | 3 |
| iGMDRD489 | GSK-461364 | 1 |
| iGMDRD144 | NSC95397 | 3 |
| iGMDRD599 | Salermide | 3 |
| iGMDRD1008 | SR-II-138A | 6 |
| iGMDRD634 | SCHEMBL2608041 | 3 |
| iGMDRD280 | CYTOCHALASIN B | 3 |
| iGMDRD608 | Refametinib | 1 |
| iGMDRD261 | OSI-027 | 1 |
| iGMDRD557 | MGCD-265 | 1 |
| iGMDRD700 | AUY922 | 1 |
| iGMDRD298 | L-685458 | 1 |
| iGMDRD320 | PIK-93 | 1 |
| iGMDRD1039 | X681640 | 1 |
| iGMDRD701 | NVP-AUY922 | 3 |
| iGMDRD160 | Cis-Platin | 1 |
| iGMDRD410 | Ko-143 | 1 |
| iGMDRD262 | KU-55933 | 1 |
| iGMDRD404 | PD318088 | 1 |
| iGMDRD177 | Teniposide | 3 |
| iGMDRD450 | JNJ-26854165 | 1 |
| iGMDRD351 | GW843682X | 3 |
| iGMDRD85 | Ursolic acid | 3 |
| iGMDRD459 | RO-3306 | 1 |
| iGMDRD42 | Vorinostat | 3 |
| iGMDRD82 | Quiflapon | 3 |
| iGMDRD353 | PD0325901 | 2 |
| iGMDRD505 | Pevonedistat | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in E2F1
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.